ATE437180T1 - Multimere formen von liganden der tnf- superfamilie - Google Patents

Multimere formen von liganden der tnf- superfamilie

Info

Publication number
ATE437180T1
ATE437180T1 AT00919485T AT00919485T ATE437180T1 AT E437180 T1 ATE437180 T1 AT E437180T1 AT 00919485 T AT00919485 T AT 00919485T AT 00919485 T AT00919485 T AT 00919485T AT E437180 T1 ATE437180 T1 AT E437180T1
Authority
AT
Austria
Prior art keywords
proteins
fusion proteins
tnfsf
cells
cd40l
Prior art date
Application number
AT00919485T
Other languages
English (en)
Inventor
Richard S Kornbluth
Original Assignee
Richard S Kornbluth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richard S Kornbluth filed Critical Richard S Kornbluth
Application granted granted Critical
Publication of ATE437180T1 publication Critical patent/ATE437180T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT00919485T 1999-12-09 2000-03-20 Multimere formen von liganden der tnf- superfamilie ATE437180T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/454,223 US7300774B1 (en) 1999-12-09 1999-12-09 Multimeric fusion proteins of the TNF superfamily ligands
PCT/US2000/007380 WO2001042298A1 (en) 1999-12-09 2000-03-20 Multimeric forms of tnf superfamily ligands

Publications (1)

Publication Number Publication Date
ATE437180T1 true ATE437180T1 (de) 2009-08-15

Family

ID=23803798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919485T ATE437180T1 (de) 1999-12-09 2000-03-20 Multimere formen von liganden der tnf- superfamilie

Country Status (9)

Country Link
US (3) US7300774B1 (de)
EP (2) EP2128174A1 (de)
AT (1) ATE437180T1 (de)
AU (1) AU785297B2 (de)
CA (1) CA2393659C (de)
DE (1) DE60042609D1 (de)
DK (1) DK1235853T3 (de)
ES (1) ES2329334T3 (de)
WO (1) WO2001042298A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
WO2002080955A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003217174A1 (en) * 2002-01-04 2003-07-30 Xencor Novel variants of rankl protein
US20030166559A1 (en) 2002-01-04 2003-09-04 Desjarlais John R. Dominant negative proteins and methods thereof
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
FR2840307B1 (fr) * 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
US20050143297A1 (en) * 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
EP1736482A1 (de) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Rekombinanter trimerer 4-1BB Ligand
AU2006284922B2 (en) 2005-08-30 2012-01-19 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
ES2560871T3 (es) * 2007-07-10 2016-02-23 Apogenix Gmbh Proteínas de fusión de colectina de la superfamilia de TNF
AU2013203061B2 (en) * 2007-07-10 2016-07-28 Apogenix Ag TNF superfamily collectin fusion proteins
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
WO2010003766A2 (en) 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
SG10201502330TA (en) 2009-08-03 2015-05-28 Univ Miami Method for in vivo expansion of t regulatory cells
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
WO2011119628A2 (en) 2010-03-23 2011-09-29 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
US20140193410A1 (en) * 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
WO2015116178A1 (en) * 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951199A4 (de) 2013-01-31 2016-07-20 Univ Jefferson Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
AU2014210908B2 (en) * 2013-02-04 2019-02-14 University Of Huddersfield Composition comprising a TNFR agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
AU2014233114B2 (en) 2013-03-15 2018-03-08 Richard S. Kornbluth Composition comprised of antigen linked to a TNF SuperFamily ligand
JP2014218510A (ja) * 2014-08-11 2014-11-20 アポゲニクスゲゼルシャフト ミット ベシュレンクテルハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
EP3606949A1 (de) * 2017-04-06 2020-02-12 Universität Stuttgart Proteinkomplex zur bindung des tumornekrosefaktors (tnfr) mit verbesserter bindung und biowirkung
AU2020301529B2 (en) 2019-06-24 2026-03-26 Universität Stuttgart TNFR2 agonists with improved stability
WO2021008501A1 (en) * 2019-07-12 2021-01-21 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered vaccinia virus
WO2021072127A2 (en) 2019-10-08 2021-04-15 Fred Hutchinson Cancer Research Center Engineered trimeric cd70 proteins and uses thereof
CN112552415B (zh) * 2021-02-22 2021-06-22 北京百普赛斯生物科技股份有限公司 B淋巴细胞刺激因子十二聚体及其制备方法与应用
CN117916274A (zh) * 2021-06-17 2024-04-19 卡利威尔免疫治疗公司 Tnfsf-l融合蛋白及其用途
EP4508071A1 (de) * 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
HUP0003762A3 (en) 1997-07-18 2005-11-28 Zymogenetics Inc Adipocyte-specific protein homologs
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2000286319A (ja) 1999-03-31 2000-10-13 Canon Inc 基板搬送方法および半導体製造装置
AU6934600A (en) 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US20040248801A1 (en) 2000-03-21 2004-12-09 Kiessling Laura L. Methods and reagents for regulation of cellular responses in biological systems
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
WO2003068799A2 (en) 2002-02-11 2003-08-21 The Trustees Of The University Of Pennsylvania Oligomeric molecules and uses thereof

Also Published As

Publication number Publication date
EP1235853B1 (de) 2009-07-22
CA2393659C (en) 2016-01-05
ES2329334T3 (es) 2009-11-25
WO2001042298A1 (en) 2001-06-14
DK1235853T3 (da) 2009-11-23
DE60042609D1 (de) 2009-09-03
EP1235853A1 (de) 2002-09-04
US20090263348A1 (en) 2009-10-22
CA2393659A1 (en) 2001-06-14
AU785297B2 (en) 2007-01-04
EP1235853A4 (de) 2004-03-31
US7300774B1 (en) 2007-11-27
AU4016700A (en) 2001-06-18
US7332298B2 (en) 2008-02-19
US20050158831A1 (en) 2005-07-21
EP2128174A1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
DE60042609D1 (de) Multimere formen von liganden der tnf-superfamilie
Mao et al. Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation
Taulier et al. Compressibility of protein transitions
CN112514892B (zh) 一种外泌体冻存保护液及其制备方法
WO2000060051A8 (en) Arpe-19 as a platform cell line for encapsulated cell-based delivery
DE60003933D1 (de) Verfahren zur herstellung von mikropartikeln
EP1689425B8 (de) Pharmazeutische formulierungen für die verzögerte freisetzung von ein oder mehr wirkstoffen und ihre therapeutische anwendungen
RU2008137634A (ru) Способ уменьшения агрегации белка
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
Rippner Blomqvist et al. Disruption of viscoelastic β-lactoglobulin surface layers at the air− water interface by nonionic polymeric surfactants
WO2005000235A3 (en) NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME
MXPA05011050A (es) Uso de b7-h3 como un agente inmunoregulador.
ATE378590T1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
EE03224B1 (et) Prolongeeritud toimega süstesuspensioonid ja nende valmistamismeetod
ES2157900T3 (es) Nuevos conjugados de proteinas y policationes.
Back et al. Hydrogel-based strategies for managing rheumatoid arthritis: from sustained drug release to cell-based therapies
BRPI0407649A (pt) formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DK1684792T3 (da) Farmaceutiske formuleringer til langvarig frisætning af interleukiner og deres terapeutiske anvendelse
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
ES2150421T3 (es) Nuevos conjugados, consistentes en una glicoproteina y una sustancia que se fija a acidos nucleicos.
PE20020960A1 (es) Concentracion y lisis de celulas infectadas por adenovirus en una unica operacion unitaria
An et al. An Intracellular Gelated Macrophage-Based Vaccine for Tumor Immunotherapy
KR890011604A (ko) 고요오드를 함유한 담수 클로렐라로부터의 열수 추출물의 제조 방법 및 그 용도

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1235853

Country of ref document: EP